Skip to main content
Fig. 9 | Stem Cell Research & Therapy

Fig. 9

From: Therapeutic effects of human gingiva-derived mesenchymal stromal cells on murine contact hypersensitivity via prostaglandin E2–EP3 signaling

Fig. 9

GMSCs attenuate CHS via PGE2–EP3 signaling. a PGE2–EP3 pathway. b IGMSCs significantly reversed the inhibitory effect of GMSCs on CHS appearance, and the application of PGE2 and IGMSCs significantly suppressed CHS appearance compared with IGMSCs alone. n = 5 independent animals. c Subcutaneous administration of PGE2 (5–20 μg/kg) led to a dose-dependent suppression of CHS appearance; the suppression of CHS appearance was statistically significant following application of 10 or 15 μg/kg PGE2. n = 5 independent animals. d Western blot showed increased production of EP3 and reduced production of EP1, EP2, and EP4 in GMSC-treated local inflammatory tissue. n = 3 independent animals/group. e Subcutaneous application of sulprotone led to a significant suppression of CHS. n = 5 independent animals. *p < 0.05; **p < 0.01. GMSC gingiva-derived mesenchymal stromal cell, IGMSC indomethacin-pretreated GMSC, CHS contact hypersensitivity, PGE 2 prostaglandin E2

Back to article page